On July 25, 2022 Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), a company developing new approaches for the treatment of cancer and fibrosis, reported that an abstract describing the Company’s ACCENT clinical trial of AMP945 in first-line patients with advanced pancreatic cancer has been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on Pancreatic Cancer, being held from September 13-16 in Boston, MA (Press release, Amplia Therapeutics, JUL 25, 2022, View Source;[email protected] [SID1234616890]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be entitled "Rationale for the use of pulsed rather than continual dosing of the novel Focal Adhesion Kinase inhibitor AMP945 in pancreatic cancer" and will describe the scientific rationale and clinical trial design for ACCENT. The trial is currently open for recruitment and has been registered on ClinialTrials.gov with an identifier number of NCT05355298.

"The AACR (Free AACR Whitepaper) special topic meetings attract the world’s leading cancer researchers who are working at the cutting edge of cancer research and new drug development. We’re delighted to have Amplia’s work accepted for presentation in this forum and expect it will raise awareness in the global clinical community of AMP945 and its potential in this devastating cancer."

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.